Patents Assigned to Juno Therapeutics, Inc.
-
Publication number: 20210393691Abstract: The present disclosure provides cell populations enriched for CD57 negative T cells, or depleted for CD57 positive cells, and methods for stimulating, cultivating, expanding, and/or genetically engineering cell populations enriched for CD57? T cells or depleted for CD57+ T cells. Also included are methods for generating, isolating, enriching, or selecting CD57? T cells or depleting CD57+ cells, such as by negative selection.Type: ApplicationFiled: November 5, 2019Publication date: December 23, 2021Applicant: Juno Therapeutics, Inc.Inventors: Sara COOPER, Daniel COSSETTE, Ryan LARSON, Jeffrey TEOH
-
CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)
Publication number: 20210393689Abstract: Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy.Type: ApplicationFiled: October 31, 2019Publication date: December 23, 2021Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer CenterInventors: Blythe D. SATHER, Eric L. SMITH, Cyr DE IMUS, Kimberly HARRINGTON, Jon JONES, Aye CHEN, Semih TAREEN, Erik HESS, Stefan PONKO, Audrey OLSHEFSKY, Carlos FERNANDEZ DE LARREA, Renier BRENTJENS -
Publication number: 20210363258Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV16 E6 and HPV16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: July 23, 2021Publication date: November 25, 2021Applicant: Juno Therapeutics, Inc.Inventors: James SISSONS, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
-
Publication number: 20210324100Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.Type: ApplicationFiled: June 21, 2021Publication date: October 21, 2021Applicants: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer CenterInventors: Blythe D. SATHER, Eric L. SMITH, Rupesh AMIN, Aye CHEN, Kimberly HARRINGTON, Collin HAUSKINS, Erik HESS, Cyr DE IMUS, Jon JONES, Audrey OLSHEFSKY, Stefan PONKO, Ruth SALMON, Semih TAREEN, Rebecca WU, Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS, Mariana Cota STIRNER, Melissa WORKS
-
Publication number: 20210284709Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: September 28, 2018Publication date: September 16, 2021Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron BRANDT, Brian BELMONT, Christopher BORGES, Stephen Michael BURLEIGH, Alexandra CROFT, Stephen Jacob GOLDFLESS, David Jeffrey HUSS, Yue JIANG, Timothy G. JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Christopher Heath NYE, Haley PEPER, Blythe D. SATHER, Sonia TIMBERLAKE, Dean Y. TOY, Queenie VONG, Gordon Grant WELSTEAD, James SISSONS
-
Publication number: 20210254000Abstract: Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.Type: ApplicationFiled: November 1, 2018Publication date: August 19, 2021Applicants: Juno Therapeutics, Inc., Celgene CorporationInventors: Archana BRAHMANDAM, Lucas James THOMPSON, Deborah MORTENSEN, Ellen FILVAROFF
-
Publication number: 20210255173Abstract: Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.Type: ApplicationFiled: April 13, 2018Publication date: August 19, 2021Applicant: Juno Therapeutics, Inc.Inventors: Paul Ken KODAMA, Tom KOWSKI, Mirna MUJACIC, Kenneth Mayo PRENTICE
-
Publication number: 20210238309Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: ApplicationFiled: December 14, 2020Publication date: August 5, 2021Applicant: Juno Therapeutics, Inc.Inventors: Yan CHEN, Steven M. SHAMAH, Csaba PAZMANY, Jui DUTTA-SIMMONS
-
Publication number: 20210230671Abstract: Provided are methods for assessing nucleic acid sequences integrated into a genome of a genetically engineered cell, such as a genetically engineered cell used in cell therapy. Cells are generally genetically engineered to express a recombinant protein, such as a recombinant receptor, via introduction of a polynucleotide and integration of certain sequences in the polynucleotide, such as recombinant sequences, into the genome of the cell. In some aspects, the provided methods can be used to distinguish integrated nucleic acids and non-integrated, residual nucleic acids.Type: ApplicationFiled: August 9, 2019Publication date: July 29, 2021Applicant: Juno Therapeutics, Inc.Inventor: Adrian Wrangham BRIGGS
-
Patent number: 11072660Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: October 3, 2017Date of Patent: July 27, 2021Assignee: Juno Therapeutics, Inc.Inventors: James Sissons, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
-
Patent number: 11066475Abstract: Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.Type: GrantFiled: November 1, 2018Date of Patent: July 20, 2021Assignees: Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer CenterInventors: Blythe D. Sather, Eric L. Smith, Rupesh Amin, Aye Chen, Kimberly Harrington, Collin Hauskins, Erik Hess, Cyr De Imus, Jon Jones, Audrey Olshefsky, Stefan Ponko, Ruth Salmon, Semih Tareen, Rebecca Wu, Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons, Mariana Cota Stirner, Melissa Works
-
Publication number: 20210207080Abstract: Provided herein is a serum-free media for culturing, such as cultivating, preparing and/or producing cells, such as immune cells, such as genetically engineered cells. Also provided is a liquid basal media and frozen supplements that can be used to produce serum-free media. The provided embodiments include methods for producing serum-free media and methods for culturing cells, such as activating, transducing, cultivating or expanded cells, in the presence of serum-free media.Type: ApplicationFiled: December 7, 2018Publication date: July 8, 2021Applicant: Juno Therapeutics, Inc.Inventors: Pascal BEAUCHESNE, Kien KHUU-DUONG, Ivie AIFUWA, Calvin CHAN
-
Publication number: 20210198372Abstract: Provided are methods of treatment, such as methods involving administering and/or determining dosing of, cell therapy, such as of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range and/or window for dosing, for example, based on the estimated probabilities of risk of developing a toxicity and estimated probabilities of a treatment outcome or response, such as treatment, reduction nor amelioration of a sign or symptom thereof, or degree or durability thereof, following administration of the cell therapy or engineered cells. In some aspects, the methods involve administering an agent capable of modulating the engineered cells. Also provided are methods of ameliorating and/or treating a toxicity.Type: ApplicationFiled: November 30, 2018Publication date: July 1, 2021Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Jacob Randolph GARCIA, Mark J. GILBERT, Jens HASSKARL, Mark D. HEIPEL, He LI, Claire L. SUTHERLAND, Nikolaus Sebastian TREDE
-
Publication number: 20210180014Abstract: Provided herein are reporter T-cells containing a reporter operably linked to the Nur77 locus. Also provided are methods for screening for an activity of a recombinant receptor, including those containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR), including assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells for one or more property or activity. The methods can be high-throughput.Type: ApplicationFiled: November 1, 2018Publication date: June 17, 2021Applicant: Juno Therapeutics, Inc.Inventors: Amin RUPESH, Aye CHEN
-
Publication number: 20210163893Abstract: The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and/or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated.Type: ApplicationFiled: August 9, 2019Publication date: June 3, 2021Applicant: Juno Therapeutics, Inc.Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Divya VARUN, Keenan BASHOUR, Robert Guy CASPARY, Calvin CHAN
-
Publication number: 20210164062Abstract: Provided are methods of detecting replication competent virus, e.g., replication competent retrovirus such as gammaretrovirus or lentivirus, in a sample containing a cell transduced with a viral vector particle encoding a recombinant and or heterologous molecule, e.g., heterologous gene product. The methods may include assessing transcription of one or more target genes, such as viral genes, that are expressed in a retrovirus but not expressed in the viral vector particle. Replication competent retrovirus may be determined to be present if the levels of RNA of the one or more target genes is higher than a reference value, which can be measured directly or indirectly, including from a positive control sample containing RNA from the respective target gene at a known level and/or at or above the limit of detection of the assay.Type: ApplicationFiled: January 31, 2019Publication date: June 3, 2021Applicant: Juno Therapeutics, Inc.Inventors: Ruth BERRY, Edwin WEBB
-
Patent number: 11020429Abstract: Provided are cells, e.g., engineered immune cells, expressing recombinant or engineered molecules involved in metabolic pathways, such as those that promote or inhibit one or more metabolic steps, reactions, or pathways, for example, in T cells. Such molecules include those that induce or repress a particular functional outcome or metabolic event, for example, one that promotes differentiation or reprogramming into a particular phenotypic state, such as memory, long-lived, activated or activatable, non-exhausted, phenotype or stem-like phenotype. The cells generally further express an immune receptor, such as an antigen receptor, which may be an engineered receptor, such as a CAR or recombinant TCR, or may be a natural immune receptor. Also provided are cells, such as T cells, expressing such molecules and combinations thereof, compositions comprising such cells, nucleic acids such as vectors encoding the same, and methods of administration to subjects in adoptive cell therapy.Type: GrantFiled: November 4, 2016Date of Patent: June 1, 2021Assignee: Juno Therapeutics, Inc.Inventor: Lucas James Thompson
-
Publication number: 20210128616Abstract: Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.Type: ApplicationFiled: December 7, 2018Publication date: May 6, 2021Applicant: Juno Therapeutics, Inc.Inventors: Kedar Himanshu DAVE, Todd DEVRIES, Ronald James HAUSE, Jr., Ryan P. LARSON, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Nathan K. YEE, Rachel K. YOST
-
Publication number: 20210128619Abstract: Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.Type: ApplicationFiled: November 4, 2020Publication date: May 6, 2021Applicants: CELGENE CORPORATION, JUNO THERAPEUTICS, INC., BRISTOL-MYERS SQUIBB COMPANYInventors: Timothy CAMPBELL, Ronald HAUSE, Kristen HEGE, Yue JIANG, Shari KAISER, Ethan THOMPSON, Jaymes FULLER, Nathan MARTIN, Rong LIU, Justine DELL'ARINGA
-
Publication number: 20210132042Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting likelihood of the subject responding to a therapy, such as a cell therapy, e.g., a chimeric antigen receptor (CAR) T cell therapy. In some aspects, the predicting is based on detecting certain biomarkers of immune cells associated with and/or that correlate with response following administration of the therapy. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is likely to respond to the therapy. The present disclosure also provides methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment the biomarker. Also provided herein are reagents and kits for performing the methods.Type: ApplicationFiled: October 31, 2018Publication date: May 6, 2021Applicant: Juno Therapeutics, Inc.Inventors: Trevor DO, Howard STERN, Christina SWANSON